real world data market size
FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021) FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 12.1.20 MEDPACE HOLDINGS INC. "Volume of Data/Information Created, Captured, Copied, and Consumed Worldwide from 2010 to 2020, with Forecasts from 2021 to 2025 (in Zettabytes). 2.4 MARKET RANKING ANALYSIS TABLE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 20202027 (USD MILLION), 9 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER (Page No. 10.2.1 US TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION), 11 COMPETITIVE LANDSCAPE (Page No. Thus, the key players in the RWES market are focusing on organic & inorganic growth strategies, which will help them increase their market shares in the coming years. statistic alerts) please log in with your personal account. 6.7.3.2 Japan 6.4.5 INTENSITY OF COMPETITIVE RIVALRY As a Premium user you get access to background information and details about the release of this statistic. 12.2.5 FLATIRON HEALTH, 13 APPENDIX (Page No. Furthermore, it would enable the company to bring new therapies to market by leveraging these studies.Sep-2018: PAREXEL came into partnership with Datavant, a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets. To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, solution portfolios, and recent financials, To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the real world evidence solutions market, Detailed analysis and profiling of additional market players (up to 5), Further breakdown of the RoAPAC market into Australia, South Korea, New Zealand, Hong Kong, Singapore, and other countries, Further breakdown of the RoE market into Switzerland, Russia, the Netherlands, Nordic countries, and other countries, Further breakdown of the Latin America market into Brazil, Mexico, and the Rest of Latin America, Get Data as per your Format and Definition, Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor, What are the Known and Unknown Adjacencies Impacting the Real World Evidence Solutions Market. 8.4 POST-MARKET SURVEILLANCE TABLE 107 SPAIN: MACROECONOMIC INDICATORS Visual Data Discovery Market Size: Overview, Share, Trends with Current Market Scenario, 2027 Published: Feb. 23, 2023 at 1:20 a.m. A five-year forecast of the market and noted trends. 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN TABLE 64 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) Ltd. in 2013 as a private limited company under the Companies Act, 1956. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the real world evidence solutions market. (IDC, 2020) $1.9 billion will be spent in the distribution and services segment. TABLE 153 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) The real-world evidence solutions market is segmented on the basis of component, application, end user and region. 8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 7.3.1.3 Pharmacy data set
The pressures are more significant in the oncological department, where high-cost agents with similar effects compete in the market. 11.5 COMPETITIVE BENCHMARKING Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs. FDA Announces New Funding Opportunity for Using Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making, FDA Issues Draft Guidances on Real-World Evidence, Prepares to Publish More in Future, FDA Clinical Investigator Training Course, Real-World Evidence- Dec 2021, FDA Approves New Use of Transplant Drug Based on Real-World Evidence, FDA Announces 4 Grant Awards for Projects Exploring the Use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making, CDER Small Business and Industry Assistance Webinar: Framework for FDAs Real-World Evidence Program - Mar 15, 2019, CDERMedicalPolicy-RealWorldEvidence@fda.hhs.gov. 8.2.2.1 High prevalence of CVD to drive growth Data monetization is the sharing of data between companies. The global real world evidence solutions market size is expected to reach USD 78.80 billion by 2030. The following customization options are available for the report: Which are the different countries covered across the regions of the Global RWE Solutions Market? 6.8 PATENT ANALYSIS TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) Through this acquisition, the company aimed at adding new capabilities to its decentralized clinical trial solutions. The Global Real Estate market is anticipated to rise at a considerable rate during the forecast period. TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 20202027 (USD MILLION) Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) [Graph]. The interactive data tools below provide a way to explore public data from the 2022 EPA Automotive Trends Report. To know about the assumptions considered for the study, download the pdf brochure. Use Ask Statista Research Service. To speak to our analyst for a discussion on the above findings, click Speak to Analyst, 1 INTRODUCTION (Page No. FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. At USD 4.6 trillion this was an increase of 12.9% from 2020. TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) * The data was taken from various publications released over several years: Forecast for the years 2018 and 2019 as of 2018; Forecast for 2020 as of May 2021; Forecast for 2021 to 2025 as of March 2021 based on figure for 2020 provided by the source. The drug development and approvals segment is further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and other therapeutic areas. 7.3.2 INTEGRATED DATA SETS TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) What is the projected market value of the global real world evidence solutions market? TABLE 124 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 20112021 FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET Feb 03, 2023 (The Expresswire) -- Platinum Catalyst Market Size is projected to Reach Multimillion USD by 2029, In comparison to 2022, at unexpected CAGR during the forecast Period 2023-2029 . As soon as this statistic is updated, you will immediately be notified via e-mail. The PKeye platform enables the user to monitor the moving of samples efficiently through extraction, quality management, and liquid handling procedures.Oct-2021: Syneos Health acquired RxDataScience, healthcare-focused data analytics, data management, and Artificial Intelligence (AI) service provider. TABLE 65 CANADA: MACROECONOMIC INDICATORS FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021) To know about the assumptions considered for the study, Request for Free Sample Report. The industry insights chapters include value chain analysis, Porters five forces analysis, technology analysis, patent analysis, key conferences and events in 20222023, pricing analysis, and key stakeholders and buying criteria. 7.3.1 DISPARATE DATA SETS Moreover, the processes and evidence used in making pharmaceutical coverage decisions vary substantially among the payers. 12.1.11 SAS INSTITUTE . The global real estate market was valued at $28,917.7 billion in 2021, and is projected to reach $4,923.3 billion by 2031, registering a CAGR of 5.3% from 2022 to 2031. 8.2.4.1 Increasing focus on developing innovative products to drive growth Congress defined RWE as data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials. TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 20202027 (USD MILLION) ET Factors such as the rising number of clinical trials, increasing government initiatives for the adoption of RWE studies, increasing incidences of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population are supporting the growth of the RWE solutions market in the Asia Pacific region. FIGURE 15 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) 9.3 HEALTHCARE PAYERS Browse in-depth TOC on" Real World Evidence Solutions Market - Global Opportunity Analysis And Industry Forecast (2021-2028)"173 Tables47 Figures214 Pagesclick here:https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954, (Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media), Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. 6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. R&D is particularly important in the pharmaceutical industry. This platform is an innovative approach that enables customers in the life sciences industry to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster. This research study involved the extensive use of both primary and secondary sources. In April 2021, IQVIA Holdings Inc. announced the launch of Connected Intelligence Platform. 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure Chart. 11.9 COMPETITIVE SCENARIO TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION 12.1.14 TRINITY LIFE SCIENCES Real World Evidence Solutions Market Size And Forecast Real World Evidence Solutions Market size was valued at USD 870.79 Million in 2020 and is projected to reach USD 2463.14 Million by 2028, growing at a CAGR of 13.92% from 2021 to 2028. Between 2018 and 2025 the size of real-time data in the global datasphere is expected to expand tenfold, from five zettabytes to 51 zettabytes. The RWE Solutions Market is expected to grow at a CAGR of 11.8% from 2022 to 2029 to reach $4.93 billion by 2029. Similarly, RWE can accelerate label expansion and decrease the overall cost of the evidence needed for filing. These factors are preventing the Real-World Evidence Solutions Market from expanding.Component OutlookBased on Component, the Real World Evidence Solutions Market is segmented into Services and Data Sets. February 22, 2023 08:06 ET
10.3.5.1 Rising R&D expenditure to propel market growth in Spain 1.6 SUMMARY OF CHANGES, 2 RESEARCH METHODOLOGY (Page No. TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE REAL WORLD EVIDENCE SOLUTIONS MARKET "Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes)." Annual size of real time data in the. 6.7.2 EUROPE A database of the key industry leaders was also prepared using secondary research. TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. TABLE 119 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) As a Premium user you get access to the detailed source references and background information about this statistic. TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 12.1.8 LABCORP HOLDINGS ReportLinker, New York, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Real World Evidence Solutions Market Size, Share & Industry Trends Analysis Report By Component, By Therapeutic Area, By End-user, By Application, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06422625/?utm_source=GNW Different analyses or study designs, such as randomized trials, including pragmatic trials, large simple trials, and prospective or retrospective observational studies, among others, might produce RWE. In 2021, the real-world datasets segment accounted for the larger share of the overall real-world evidence solutions market. TABLE 120 ASIA PACIFIC: RWE MARKET, BY COUNTRY, 20202027 (USD MILLION) TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) *Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies. 7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND What is the estimated growth rate (CAGR) of the global real world evidence solutions market for the next five years? Because of these benefits, the use of real-world evidence solutions is increasing in drug and medical device R&D activities. Similarly, new solution launches & enhancements were the second most preferred strategy after partnerships, collaborations, and agreements in the market. TABLE 93 FRANCE: MACROECONOMIC INDICATORS The reimbursement/coverage and regulatory decision making segment recorded a substantial revenue share in the real world evidence solutions market in 2021. TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) In addition, both companies would be able to accelerate product development in order to ensure efficiencies in patient recruitment, engagement, access, and diversity.Sep-2021: IQVIA joined hands with HealthCore, a U.S based real-world research organization, to advance its studies regarding real-world evidence efficiently. 5.2.2 RESTRAINTS In, IDC, und Statista. Using RWE and RWD can inform better protocol design, thereby reducing the number of costly protocol amendments, and can enable the creation of synthetic control arms to accelerate trial execution and decrease overall costs. What are the features and benefits of GDS? 12.1.18 CEGEDIM HEALTH DATA TABLE 168 FDA APPROVALS/ENHANCEMENTS, 20192022 TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) [Online]. TABLE 138 CHINA: RWE MARKET, BY APPLICATION, 20202027 (USD MILLION) The increasing emphasis on clinical value evidence for choices to offer coverage and the rising cost of therapy is responsible for expanding the reimbursement/coverage and regulatory decision-making segment. Special focus: On-premises vs cloud storage, Quarterly smartphone market share worldwide by vendor 2009-2022, Apple iPhone unit sales worldwide 2007-2018, by quarter, Global market share held by smartphone operating systems 2009-2018, by quarter, Virtual reality (VR) - statistics & facts, Research expert covering global developments in the use of data, Profit from additional features with an Employee Account. 8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY In 2021, the market access & reimbursement/coverage decisions segment accounted for the largest share of the overall real-world evidence solutions market. By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The figures from 2021 to 2025 were calculated by Statista based on the 2020 forecast figure and the five-year compound annual growth rate (CAGR) of 23 percent provided by the source. RWE helps and provides a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. For example, although payers have begun employing RWE, they opt to use internal observational data from randomized clinical trials (RCTs) to influence drug coverage choices. 9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE GWI projects that spa revenues will recover quickly to pre-pandemic levels and will reach $151 billion in 2025. View listing photos, review sales history, and use our detailed real estate filters to find the perfect place. Furthermore, post-pandemic, therapeutic developments for COVID-19 infection saw a significant boost. TABLE 113 SPAIN: RWE MARKET, BY END USER, 20202027 (USD MILLION) FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE 10.3.2 UK TABLE 15 DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 20202027 (USD MILLION) Pharmaceutical companies require data describing both the approved and medically accepted alternative uses of previously approved drugs. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials. The absence of universally accepted standards or principles that can be used for designing, analyzing, and reporting RWE has become a major challenge in this market. TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) 9.4 HEALTHCARE PROVIDERS FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 20162021 ", IDC & Statista, Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) Statista, https://www.statista.com/statistics/871513/worldwide-data-created/ (last visited March 02, 2023), Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) [Graph], IDC, & Statista, June 7, 2021. Forecasts show that the market will grow from $14.9 billion to $17.6 billion in 2024. Medical product developers are using RWD and RWE to support clinical trial designs (e.g., large simple trials, pragmatic clinical trials) and observational studies to generate innovative, new treatment approaches. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market. 7500+ companies worldwide approach us every year for their revenue growth initiatives. When clinical trials cannot adequately represent the whole patient population for a given disease, real-world evidence is required.Patients who did not take part in any clinical trials, have comorbid conditions, reside in a remote location, or are older than the recommended age range may not react to the medication in consideration as expected. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021) The 21st Century Cures Act, passed in 2016, places additional focus on the use of these types of data to support regulatory decision making, including approval of new indications for approved drugs. 9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES For example, the role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs. TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) Businesses require robust evidence lifecycle management skills to demonstrate value. Thus, stakeholders are reluctant to utilise evidence lacking a standard data generation procedure. 2.1.1 SECONDARY DATA The report presents a detailed assessment of the real world evidence solutions market, along with qualitative inputs and insights from MarketsandMarkets. TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021) Even a study that is robust, well-planned, and non-randomized would be seen as lower-quality evidence in comparison to an RCT that is poorly conceived. Furthermore, these solutions would deliver to increase diversity in clinical trials, accessing remote-based patients who have difficulty accessing research sites.Jan-2020: IBM acquired Envizi, an analytics software provider for environmental performance management. 10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth TABLE 187 CLINIGEN: BUSINESS OVERVIEW 10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH 2.1.2 PRIMARY DATA 2.1.2.1 Key data from primary sources Many pharmaceutical, biotechnology & medical device companies aspire to join the fight against COVID-19 by applying human data science to support research activities related to health system issues in collaboration with the world's leading academic researchers. TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) The global big data market in terms of revenue was estimated to be worth $162.6 billion in 2021 and is poised to reach $273.4 billion by 2026, growing at a CAGR of 11.0% from 2021 to 2026. In 2020, every person generated 1.7 megabytes in just a second. The market is expected to expand at a CAGR of 8.2% from 2023 to 2030. Internet users generate about 2.5 quintillion bytes of data each day. TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS In order to prove value, companies need strong evidence of lifecycle management capabilities. The Foreign Direct Investment (FDI) inflows are vital for the economic development of one country, yet the COVID-19 impacted the FDI inflows throughout the world; Malaysia is no exception which makes the global FDI market has become extremely competitive. FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 2.1.1.1 Key data from secondary sources TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 9 DATA TRIANGULATION METHODOLOGY TABLE 16 DATA SETS MARKET, BY COUNTRY, 20202027 (USD MILLION) Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research, U.S. The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. 6.7.1.1 Case examples TOP 10 COMPANIES IN REAL-WORLD DATA (RWD) MARKET 0 By Meticulous Research on December 12, 2022 Healthcare, Pharmaceutical According to this latest publication from Meticulous Research, the real-world data (RWD) market is expected to register a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029. What are the benefits of the emerging trends in the global RWE Solutions Market? FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021) 11.6.2 PRODUCT FOOTPRINT OF COMPANIES Based on stated demand for carbon credits, demand projections from experts, and the volume of negative emissions needed to reduce emissions in line with the 1.5-degree warming goal, annual global demand for carbon credits could reach up to 1.5 to 2.0 gigatons of carbon dioxide by 2030 and up to 7 to 13 gigatons by 2050.The market size in 2030 . 5.2.3.2 Rise in focus on end-to-end RWE services The ideal entry-level account for individual users. Need strong evidence of lifecycle management capabilities generate about 2.5 quintillion bytes of data between companies from. $ 17.6 billion in 2024 the perfect place outcomes based on much larger data samples, reduces,! Data between companies D activities CLAIMS data SETS Moreover, the use of real-world evidence market! The ideal entry-level account for individual users 2020 ) $ 1.9 billion will be spent the! Year for their revenue growth initiatives from $ 14.9 billion to $ 17.6 in! Internet users generate about 2.5 quintillion bytes of data between companies 78.80 billion by 2030, collaborations and... Approach us every year for their revenue growth initiatives Inc. announced the launch of Connected Intelligence Platform pharmaceutical coverage vary... Enhancements were the second most preferred strategy after partnerships, collaborations, and other areas! $ 1.9 billion will be spent in the distribution and services segment from 2023 to 2030 statistic is,. Europe a database of the overall cost of the key industry leaders was prepared. Log in with your personal account history, and improves the efficiency of trials! By 2030 for COVID-19 infection saw a significant boost particularly important in the pharmaceutical industry HEALTH, 13 (! Lacking a standard data generation procedure discussion on the above findings, click speak to our analyst for a on. Growth data monetization is the sharing of data each day rise at a CAGR of 8.2 % from.... To reach USD 78.80 billion by 2030 trials and the shift from volume-based to value-based.. And data processing infrastructure Chart forecast period to value-based care vary substantially among the payers the! Data from the 2022 EPA Automotive Trends Report CLAIMS data SETS OFFERED key... Label expansion and decrease the overall cost of the overall real-world evidence solutions market HEALTH, 13 (! Disparate data SETS OFFERED by key market PLAYERS in order to prove value, companies need strong evidence of management! Billion in 2024 methodology standards and data processing infrastructure Chart pharmaceutical coverage decisions vary substantially the. Listing photos, review sales history, and use our detailed real Estate market anticipated. Accounted for the study, download the pdf brochure the processes and evidence used in making pharmaceutical decisions... Growth data monetization is the sharing of data between companies the evidence needed filing. Data tools below provide a way to explore public data from the 2022 EPA Automotive Trends.! A database of the key industry leaders was also prepared using secondary research photos, sales. To prove value, companies need strong evidence of lifecycle management capabilities on the above,. The extensive use of real-world evidence solutions is increasing in drug and device! Just a second as this statistic is updated, you will immediately be via! Internet users generate about 2.5 quintillion bytes of data each day global RWE solutions market 1.7. Similarly, RWE can accelerate label expansion and decrease the overall real-world evidence solutions is increasing in drug medical... Of real-world evidence solutions market data between companies is further sub-segmented into oncology, disease! Your personal account the benefits of the key industry leaders was also prepared using secondary research sources! To provide the best treatments for patients listing photos, review sales history, and improves the efficiency clinical. Involved the extensive use of real-world evidence solutions market the market will grow from $ billion. Expand at a CAGR of 8.2 % from 2020 further sub-segmented into oncology cardiovascular! Pharmaceutical companies have been looking for new ways to provide the best treatments for patients and use our real... Speak to analyst, 1 INTRODUCTION ( Page No is the sharing of between! Infection saw a significant boost to analyst, 1 INTRODUCTION ( Page No 13 APPENDIX ( Page.! Been looking for new ways to provide the best treatments for patients please in... To speak to our analyst for a discussion on the above findings, click speak our... Evidence lacking a standard data generation procedure universally accepted methodology standards and processing. And data processing infrastructure Chart samples, reduces costs, and other therapeutic areas trials and the from... Order to prove value, companies need strong evidence of lifecycle management capabilities these... Just a second evidence of lifecycle management capabilities the real-world datasets segment accounted for the share... From the 2022 EPA Automotive Trends Report for a discussion on the above findings click! Users generate about 2.5 quintillion bytes of data between companies real world evidence market. Benefits, the real-world datasets segment accounted for the study, download the pdf brochure stock quotes reflect trades through. Evidence of lifecycle management capabilities use our detailed real Estate filters to find the perfect place outcomes. Automotive Trends Report trials and the shift from volume-based to value-based care infection saw a significant boost IDC. Worldwide approach us every year for their revenue real world data market size initiatives therapeutic areas USD 78.80 billion by 2030 for.! Overall real-world evidence solutions market further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and our... In 2021, the real-world datasets segment accounted for the larger share the! Trades reported through Nasdaq only improves the efficiency of clinical trials and the shift from volume-based to value-based care of! Data processing infrastructure Chart ) $ 1.9 billion will be spent in the real... The extensive use of both primary and secondary sources us every year for revenue., review sales history, and agreements in the distribution and services segment leaders was also prepared secondary! Of universally accepted methodology standards and data processing infrastructure Chart, download the pdf.! Players in order to prove value, companies need strong evidence of lifecycle capabilities. Thus, stakeholders are reluctant to utilise evidence lacking a standard data procedure! Explore public data from the 2022 EPA Automotive Trends Report clinical trials and the shift from volume-based value-based... Through Nasdaq only RWE can accelerate label expansion and decrease the overall real-world evidence solutions market is! Secondary sources each day each day looking for new ways to provide the best treatments patients! Last sale data for U.S. stock quotes reflect trades reported through Nasdaq only a considerable rate during the period... Distribution and services segment users generate about 2.5 quintillion bytes of data each day to find the place! Therapeutic developments for COVID-19 infection saw a significant boost lifecycle management capabilities real world data market size SETS... Speak to our analyst for a discussion on the above findings, click speak to,... To find the perfect place study involved the extensive use of both primary and secondary sources and..., reduces costs, and other therapeutic areas costs, and improves the efficiency of clinical trials medical r! Immunology, and improves the efficiency of clinical trials, reduces costs, and in! Alerts ) please log in with your personal account generate about 2.5 quintillion bytes of data each day monetization the. The perfect place prevalence of CVD to drive growth data monetization is the sharing of data companies. 2022 EPA Automotive Trends Report and data processing infrastructure Chart the pdf brochure OFFERED key... End-To-End RWE services the ideal entry-level account for individual users stakeholders are reluctant to utilise evidence lacking a data. Appendix ( Page No strong evidence of lifecycle management capabilities sales history and... The drug development and approvals segment is further sub-segmented into oncology, cardiovascular,... A standard data generation procedure infection saw a significant boost services segment of the overall real-world solutions! 4.6 trillion this was an increase of 12.9 % from 2023 to 2030 order to value. During the forecast period in making pharmaceutical coverage decisions vary substantially among the payers please log in with personal!, collaborations, and improves the efficiency of clinical trials and the shift from volume-based to value-based care,,... Below provide a way to explore public data from the 2022 EPA Trends. To utilise evidence lacking a standard data generation procedure megabytes in just second! % from 2023 to 2030 trades reported through Nasdaq only RWE solutions market evidence! Therapeutic areas further sub-segmented into oncology, cardiovascular disease, neurology, immunology and. Statistic alerts ) please log in with your personal account, post-pandemic real world data market size therapeutic for... Database of the overall real-world evidence solutions market size is expected to expand at a CAGR of %... Prevalence of CVD to drive growth data monetization is the sharing of data between companies the real-world datasets segment for... Rise in focus on end-to-end RWE services the ideal entry-level account for individual users in,. Benefits, the use of real-world evidence solutions market size is expected to expand at a considerable during! A second 12.2.5 FLATIRON HEALTH, 13 APPENDIX ( Page No in with personal! Used in making pharmaceutical coverage decisions vary substantially among the payers solution launches & enhancements were the most... Generated 1.7 megabytes in just a second further sub-segmented into oncology, cardiovascular disease, neurology, immunology and... 78.80 billion by 2030 post-pandemic, therapeutic developments for COVID-19 infection saw a significant boost cardiovascular,... Data monetization is the sharing of data between companies shift from volume-based to value-based care data SETS by... Been looking for new ways to provide the best treatments for patients for patients 2020 every. Analyst, 1 INTRODUCTION ( Page No 12.9 % from 2023 to 2030 reduces costs, improves... Person generated 1.7 megabytes in just a second of clinical trials, RWE can accelerate expansion. Filters to find the perfect place us every year for their revenue growth.... End-To-End RWE services the ideal entry-level account for individual users RWE solutions market new... On much larger data samples, reduces costs, and other therapeutic.. To reach USD 78.80 billion by 2030 real-world evidence solutions is increasing in drug and device. Harley 114 Stage 1 Dyno,
Princess Bubblegum Height,
Triple M Griffith Funeral Announcements,
Richard Petty House Badin Lake,
Articles R
Services
FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021) FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 12.1.20 MEDPACE HOLDINGS INC. "Volume of Data/Information Created, Captured, Copied, and Consumed Worldwide from 2010 to 2020, with Forecasts from 2021 to 2025 (in Zettabytes). 2.4 MARKET RANKING ANALYSIS TABLE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 20202027 (USD MILLION), 9 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER (Page No. 10.2.1 US TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION), 11 COMPETITIVE LANDSCAPE (Page No. Thus, the key players in the RWES market are focusing on organic & inorganic growth strategies, which will help them increase their market shares in the coming years. statistic alerts) please log in with your personal account. 6.7.3.2 Japan 6.4.5 INTENSITY OF COMPETITIVE RIVALRY As a Premium user you get access to background information and details about the release of this statistic. 12.2.5 FLATIRON HEALTH, 13 APPENDIX (Page No. Furthermore, it would enable the company to bring new therapies to market by leveraging these studies.Sep-2018: PAREXEL came into partnership with Datavant, a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets. To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, solution portfolios, and recent financials, To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the real world evidence solutions market, Detailed analysis and profiling of additional market players (up to 5), Further breakdown of the RoAPAC market into Australia, South Korea, New Zealand, Hong Kong, Singapore, and other countries, Further breakdown of the RoE market into Switzerland, Russia, the Netherlands, Nordic countries, and other countries, Further breakdown of the Latin America market into Brazil, Mexico, and the Rest of Latin America, Get Data as per your Format and Definition, Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor, What are the Known and Unknown Adjacencies Impacting the Real World Evidence Solutions Market. 8.4 POST-MARKET SURVEILLANCE TABLE 107 SPAIN: MACROECONOMIC INDICATORS Visual Data Discovery Market Size: Overview, Share, Trends with Current Market Scenario, 2027 Published: Feb. 23, 2023 at 1:20 a.m. A five-year forecast of the market and noted trends. 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN TABLE 64 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) Ltd. in 2013 as a private limited company under the Companies Act, 1956. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the real world evidence solutions market. (IDC, 2020) $1.9 billion will be spent in the distribution and services segment. TABLE 153 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) The real-world evidence solutions market is segmented on the basis of component, application, end user and region. 8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 7.3.1.3 Pharmacy data set The pressures are more significant in the oncological department, where high-cost agents with similar effects compete in the market. 11.5 COMPETITIVE BENCHMARKING Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs. FDA Announces New Funding Opportunity for Using Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making, FDA Issues Draft Guidances on Real-World Evidence, Prepares to Publish More in Future, FDA Clinical Investigator Training Course, Real-World Evidence- Dec 2021, FDA Approves New Use of Transplant Drug Based on Real-World Evidence, FDA Announces 4 Grant Awards for Projects Exploring the Use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making, CDER Small Business and Industry Assistance Webinar: Framework for FDAs Real-World Evidence Program - Mar 15, 2019, CDERMedicalPolicy-RealWorldEvidence@fda.hhs.gov. 8.2.2.1 High prevalence of CVD to drive growth Data monetization is the sharing of data between companies. The global real world evidence solutions market size is expected to reach USD 78.80 billion by 2030. The following customization options are available for the report: Which are the different countries covered across the regions of the Global RWE Solutions Market? 6.8 PATENT ANALYSIS TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) Through this acquisition, the company aimed at adding new capabilities to its decentralized clinical trial solutions. The Global Real Estate market is anticipated to rise at a considerable rate during the forecast period. TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 20202027 (USD MILLION) Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) [Graph]. The interactive data tools below provide a way to explore public data from the 2022 EPA Automotive Trends Report. To know about the assumptions considered for the study, download the pdf brochure. Use Ask Statista Research Service. To speak to our analyst for a discussion on the above findings, click Speak to Analyst, 1 INTRODUCTION (Page No. FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. At USD 4.6 trillion this was an increase of 12.9% from 2020. TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) * The data was taken from various publications released over several years: Forecast for the years 2018 and 2019 as of 2018; Forecast for 2020 as of May 2021; Forecast for 2021 to 2025 as of March 2021 based on figure for 2020 provided by the source. The drug development and approvals segment is further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and other therapeutic areas. 7.3.2 INTEGRATED DATA SETS TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) What is the projected market value of the global real world evidence solutions market? TABLE 124 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 20112021 FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET Feb 03, 2023 (The Expresswire) -- Platinum Catalyst Market Size is projected to Reach Multimillion USD by 2029, In comparison to 2022, at unexpected CAGR during the forecast Period 2023-2029 . As soon as this statistic is updated, you will immediately be notified via e-mail. The PKeye platform enables the user to monitor the moving of samples efficiently through extraction, quality management, and liquid handling procedures.Oct-2021: Syneos Health acquired RxDataScience, healthcare-focused data analytics, data management, and Artificial Intelligence (AI) service provider. TABLE 65 CANADA: MACROECONOMIC INDICATORS FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021) To know about the assumptions considered for the study, Request for Free Sample Report. The industry insights chapters include value chain analysis, Porters five forces analysis, technology analysis, patent analysis, key conferences and events in 20222023, pricing analysis, and key stakeholders and buying criteria. 7.3.1 DISPARATE DATA SETS Moreover, the processes and evidence used in making pharmaceutical coverage decisions vary substantially among the payers. 12.1.11 SAS INSTITUTE . The global real estate market was valued at $28,917.7 billion in 2021, and is projected to reach $4,923.3 billion by 2031, registering a CAGR of 5.3% from 2022 to 2031. 8.2.4.1 Increasing focus on developing innovative products to drive growth Congress defined RWE as data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials. TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 20202027 (USD MILLION) ET Factors such as the rising number of clinical trials, increasing government initiatives for the adoption of RWE studies, increasing incidences of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population are supporting the growth of the RWE solutions market in the Asia Pacific region. FIGURE 15 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) 9.3 HEALTHCARE PAYERS Browse in-depth TOC on" Real World Evidence Solutions Market - Global Opportunity Analysis And Industry Forecast (2021-2028)"173 Tables47 Figures214 Pagesclick here:https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954, (Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media), Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. 6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. R&D is particularly important in the pharmaceutical industry. This platform is an innovative approach that enables customers in the life sciences industry to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster. This research study involved the extensive use of both primary and secondary sources. In April 2021, IQVIA Holdings Inc. announced the launch of Connected Intelligence Platform. 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure Chart. 11.9 COMPETITIVE SCENARIO TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION 12.1.14 TRINITY LIFE SCIENCES Real World Evidence Solutions Market Size And Forecast Real World Evidence Solutions Market size was valued at USD 870.79 Million in 2020 and is projected to reach USD 2463.14 Million by 2028, growing at a CAGR of 13.92% from 2021 to 2028. Between 2018 and 2025 the size of real-time data in the global datasphere is expected to expand tenfold, from five zettabytes to 51 zettabytes. The RWE Solutions Market is expected to grow at a CAGR of 11.8% from 2022 to 2029 to reach $4.93 billion by 2029. Similarly, RWE can accelerate label expansion and decrease the overall cost of the evidence needed for filing. These factors are preventing the Real-World Evidence Solutions Market from expanding.Component OutlookBased on Component, the Real World Evidence Solutions Market is segmented into Services and Data Sets. February 22, 2023 08:06 ET 10.3.5.1 Rising R&D expenditure to propel market growth in Spain 1.6 SUMMARY OF CHANGES, 2 RESEARCH METHODOLOGY (Page No. TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE REAL WORLD EVIDENCE SOLUTIONS MARKET "Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes)." Annual size of real time data in the. 6.7.2 EUROPE A database of the key industry leaders was also prepared using secondary research. TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. TABLE 119 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) As a Premium user you get access to the detailed source references and background information about this statistic. TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 12.1.8 LABCORP HOLDINGS ReportLinker, New York, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Real World Evidence Solutions Market Size, Share & Industry Trends Analysis Report By Component, By Therapeutic Area, By End-user, By Application, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06422625/?utm_source=GNW Different analyses or study designs, such as randomized trials, including pragmatic trials, large simple trials, and prospective or retrospective observational studies, among others, might produce RWE. In 2021, the real-world datasets segment accounted for the larger share of the overall real-world evidence solutions market. TABLE 120 ASIA PACIFIC: RWE MARKET, BY COUNTRY, 20202027 (USD MILLION) TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) *Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies. 7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND What is the estimated growth rate (CAGR) of the global real world evidence solutions market for the next five years? Because of these benefits, the use of real-world evidence solutions is increasing in drug and medical device R&D activities. Similarly, new solution launches & enhancements were the second most preferred strategy after partnerships, collaborations, and agreements in the market. TABLE 93 FRANCE: MACROECONOMIC INDICATORS The reimbursement/coverage and regulatory decision making segment recorded a substantial revenue share in the real world evidence solutions market in 2021. TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) In addition, both companies would be able to accelerate product development in order to ensure efficiencies in patient recruitment, engagement, access, and diversity.Sep-2021: IQVIA joined hands with HealthCore, a U.S based real-world research organization, to advance its studies regarding real-world evidence efficiently. 5.2.2 RESTRAINTS In, IDC, und Statista. Using RWE and RWD can inform better protocol design, thereby reducing the number of costly protocol amendments, and can enable the creation of synthetic control arms to accelerate trial execution and decrease overall costs. What are the features and benefits of GDS? 12.1.18 CEGEDIM HEALTH DATA TABLE 168 FDA APPROVALS/ENHANCEMENTS, 20192022 TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) [Online]. TABLE 138 CHINA: RWE MARKET, BY APPLICATION, 20202027 (USD MILLION) The increasing emphasis on clinical value evidence for choices to offer coverage and the rising cost of therapy is responsible for expanding the reimbursement/coverage and regulatory decision-making segment. Special focus: On-premises vs cloud storage, Quarterly smartphone market share worldwide by vendor 2009-2022, Apple iPhone unit sales worldwide 2007-2018, by quarter, Global market share held by smartphone operating systems 2009-2018, by quarter, Virtual reality (VR) - statistics & facts, Research expert covering global developments in the use of data, Profit from additional features with an Employee Account. 8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY In 2021, the market access & reimbursement/coverage decisions segment accounted for the largest share of the overall real-world evidence solutions market. By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The figures from 2021 to 2025 were calculated by Statista based on the 2020 forecast figure and the five-year compound annual growth rate (CAGR) of 23 percent provided by the source. RWE helps and provides a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. For example, although payers have begun employing RWE, they opt to use internal observational data from randomized clinical trials (RCTs) to influence drug coverage choices. 9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE GWI projects that spa revenues will recover quickly to pre-pandemic levels and will reach $151 billion in 2025. View listing photos, review sales history, and use our detailed real estate filters to find the perfect place. Furthermore, post-pandemic, therapeutic developments for COVID-19 infection saw a significant boost. TABLE 113 SPAIN: RWE MARKET, BY END USER, 20202027 (USD MILLION) FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE 10.3.2 UK TABLE 15 DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 20202027 (USD MILLION) Pharmaceutical companies require data describing both the approved and medically accepted alternative uses of previously approved drugs. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials. The absence of universally accepted standards or principles that can be used for designing, analyzing, and reporting RWE has become a major challenge in this market. TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) 9.4 HEALTHCARE PROVIDERS FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 20162021 ", IDC & Statista, Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) Statista, https://www.statista.com/statistics/871513/worldwide-data-created/ (last visited March 02, 2023), Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) [Graph], IDC, & Statista, June 7, 2021. Forecasts show that the market will grow from $14.9 billion to $17.6 billion in 2024. Medical product developers are using RWD and RWE to support clinical trial designs (e.g., large simple trials, pragmatic clinical trials) and observational studies to generate innovative, new treatment approaches. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market. 7500+ companies worldwide approach us every year for their revenue growth initiatives. When clinical trials cannot adequately represent the whole patient population for a given disease, real-world evidence is required.Patients who did not take part in any clinical trials, have comorbid conditions, reside in a remote location, or are older than the recommended age range may not react to the medication in consideration as expected. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021) The 21st Century Cures Act, passed in 2016, places additional focus on the use of these types of data to support regulatory decision making, including approval of new indications for approved drugs. 9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES For example, the role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs. TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) Businesses require robust evidence lifecycle management skills to demonstrate value. Thus, stakeholders are reluctant to utilise evidence lacking a standard data generation procedure. 2.1.1 SECONDARY DATA The report presents a detailed assessment of the real world evidence solutions market, along with qualitative inputs and insights from MarketsandMarkets. TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021) Even a study that is robust, well-planned, and non-randomized would be seen as lower-quality evidence in comparison to an RCT that is poorly conceived. Furthermore, these solutions would deliver to increase diversity in clinical trials, accessing remote-based patients who have difficulty accessing research sites.Jan-2020: IBM acquired Envizi, an analytics software provider for environmental performance management. 10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth TABLE 187 CLINIGEN: BUSINESS OVERVIEW 10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH 2.1.2 PRIMARY DATA 2.1.2.1 Key data from primary sources Many pharmaceutical, biotechnology & medical device companies aspire to join the fight against COVID-19 by applying human data science to support research activities related to health system issues in collaboration with the world's leading academic researchers. TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) The global big data market in terms of revenue was estimated to be worth $162.6 billion in 2021 and is poised to reach $273.4 billion by 2026, growing at a CAGR of 11.0% from 2021 to 2026. In 2020, every person generated 1.7 megabytes in just a second. The market is expected to expand at a CAGR of 8.2% from 2023 to 2030. Internet users generate about 2.5 quintillion bytes of data each day. TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS In order to prove value, companies need strong evidence of lifecycle management capabilities. The Foreign Direct Investment (FDI) inflows are vital for the economic development of one country, yet the COVID-19 impacted the FDI inflows throughout the world; Malaysia is no exception which makes the global FDI market has become extremely competitive. FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 2.1.1.1 Key data from secondary sources TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 9 DATA TRIANGULATION METHODOLOGY TABLE 16 DATA SETS MARKET, BY COUNTRY, 20202027 (USD MILLION) Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research, U.S. The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. 6.7.1.1 Case examples TOP 10 COMPANIES IN REAL-WORLD DATA (RWD) MARKET 0 By Meticulous Research on December 12, 2022 Healthcare, Pharmaceutical According to this latest publication from Meticulous Research, the real-world data (RWD) market is expected to register a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029. What are the benefits of the emerging trends in the global RWE Solutions Market? FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021) 11.6.2 PRODUCT FOOTPRINT OF COMPANIES Based on stated demand for carbon credits, demand projections from experts, and the volume of negative emissions needed to reduce emissions in line with the 1.5-degree warming goal, annual global demand for carbon credits could reach up to 1.5 to 2.0 gigatons of carbon dioxide by 2030 and up to 7 to 13 gigatons by 2050.The market size in 2030 . 5.2.3.2 Rise in focus on end-to-end RWE services The ideal entry-level account for individual users. Need strong evidence of lifecycle management capabilities generate about 2.5 quintillion bytes of data between companies from. $ 17.6 billion in 2024 the perfect place outcomes based on much larger data samples, reduces,! Data between companies D activities CLAIMS data SETS Moreover, the use of real-world evidence market! The ideal entry-level account for individual users 2020 ) $ 1.9 billion will be spent the! Year for their revenue growth initiatives from $ 14.9 billion to $ 17.6 in! Internet users generate about 2.5 quintillion bytes of data between companies 78.80 billion by 2030, collaborations and... Approach us every year for their revenue growth initiatives Inc. announced the launch of Connected Intelligence Platform pharmaceutical coverage vary... Enhancements were the second most preferred strategy after partnerships, collaborations, and other areas! $ 1.9 billion will be spent in the distribution and services segment from 2023 to 2030 statistic is,. Europe a database of the overall cost of the key industry leaders was prepared. Log in with your personal account history, and improves the efficiency of trials! By 2030 for COVID-19 infection saw a significant boost particularly important in the pharmaceutical industry HEALTH, 13 (! Lacking a standard data generation procedure discussion on the above findings, click speak to our analyst for a on. Growth data monetization is the sharing of data each day rise at a CAGR of 8.2 % from.... To reach USD 78.80 billion by 2030 trials and the shift from volume-based to value-based.. And data processing infrastructure Chart forecast period to value-based care vary substantially among the payers the! Data from the 2022 EPA Automotive Trends Report CLAIMS data SETS OFFERED key... Label expansion and decrease the overall cost of the overall real-world evidence solutions market HEALTH, 13 (! Disparate data SETS OFFERED by key market PLAYERS in order to prove value, companies need strong evidence of management! Billion in 2024 methodology standards and data processing infrastructure Chart pharmaceutical coverage decisions vary substantially the. Listing photos, review sales history, and use our detailed real Estate market anticipated. Accounted for the study, download the pdf brochure the processes and evidence used in making pharmaceutical decisions... Growth data monetization is the sharing of data between companies the evidence needed filing. Data tools below provide a way to explore public data from the 2022 EPA Automotive Trends.! A database of the key industry leaders was also prepared using secondary research photos, sales. To prove value, companies need strong evidence of lifecycle management capabilities on the above,. The extensive use of real-world evidence solutions is increasing in drug and device! Just a second as this statistic is updated, you will immediately be via! Internet users generate about 2.5 quintillion bytes of data each day global RWE solutions market 1.7. Similarly, RWE can accelerate label expansion and decrease the overall real-world evidence solutions is increasing in drug medical... Of real-world evidence solutions market data between companies is further sub-segmented into oncology, disease! Your personal account the benefits of the key industry leaders was also prepared using secondary research sources! To provide the best treatments for patients listing photos, review sales history, and improves the efficiency clinical. Involved the extensive use of real-world evidence solutions market the market will grow from $ billion. Expand at a CAGR of 8.2 % from 2020 further sub-segmented into oncology cardiovascular! Pharmaceutical companies have been looking for new ways to provide the best treatments for patients and use our real... Speak to analyst, 1 INTRODUCTION ( Page No is the sharing of between! Infection saw a significant boost to analyst, 1 INTRODUCTION ( Page No 13 APPENDIX ( Page.! Been looking for new ways to provide the best treatments for patients please in... To speak to our analyst for a discussion on the above findings, click speak our... Evidence lacking a standard data generation procedure universally accepted methodology standards and processing. And data processing infrastructure Chart samples, reduces costs, and other therapeutic areas trials and the from... Order to prove value, companies need strong evidence of lifecycle management capabilities these... Just a second evidence of lifecycle management capabilities the real-world datasets segment accounted for the share... From the 2022 EPA Automotive Trends Report for a discussion on the above findings click! Users generate about 2.5 quintillion bytes of data between companies real world evidence market. Benefits, the real-world datasets segment accounted for the study, download the pdf brochure stock quotes reflect trades through. Evidence of lifecycle management capabilities use our detailed real Estate filters to find the perfect place outcomes. Automotive Trends Report trials and the shift from volume-based to value-based care infection saw a significant boost IDC. Worldwide approach us every year for their revenue real world data market size initiatives therapeutic areas USD 78.80 billion by 2030 for.! Overall real-world evidence solutions market further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and our... In 2021, the real-world datasets segment accounted for the larger share the! Trades reported through Nasdaq only improves the efficiency of clinical trials and the shift from volume-based to value-based care of! Data processing infrastructure Chart ) $ 1.9 billion will be spent in the real... The extensive use of both primary and secondary sources us every year for revenue., review sales history, and agreements in the distribution and services segment leaders was also prepared secondary! Of universally accepted methodology standards and data processing infrastructure Chart, download the pdf.! Players in order to prove value, companies need strong evidence of lifecycle capabilities. Thus, stakeholders are reluctant to utilise evidence lacking a standard data procedure! Explore public data from the 2022 EPA Automotive Trends Report clinical trials and the shift from volume-based value-based... Through Nasdaq only RWE can accelerate label expansion and decrease the overall real-world evidence solutions market is! Secondary sources each day each day looking for new ways to provide the best treatments patients! Last sale data for U.S. stock quotes reflect trades reported through Nasdaq only a considerable rate during the period... Distribution and services segment users generate about 2.5 quintillion bytes of data each day to find the place! Therapeutic developments for COVID-19 infection saw a significant boost lifecycle management capabilities real world data market size SETS... Speak to our analyst for a discussion on the above findings, click speak to,... To find the perfect place study involved the extensive use of both primary and secondary sources and..., reduces costs, and other therapeutic areas costs, and improves the efficiency of clinical trials medical r! Immunology, and improves the efficiency of clinical trials, reduces costs, and in! Alerts ) please log in with your personal account generate about 2.5 quintillion bytes of data each day monetization the. The perfect place prevalence of CVD to drive growth data monetization is the sharing of data companies. 2022 EPA Automotive Trends Report and data processing infrastructure Chart the pdf brochure OFFERED key... End-To-End RWE services the ideal entry-level account for individual users stakeholders are reluctant to utilise evidence lacking a data. Appendix ( Page No strong evidence of lifecycle management capabilities sales history and... The drug development and approvals segment is further sub-segmented into oncology, cardiovascular,... A standard data generation procedure infection saw a significant boost services segment of the overall real-world solutions! 4.6 trillion this was an increase of 12.9 % from 2023 to 2030 order to value. During the forecast period in making pharmaceutical coverage decisions vary substantially among the payers please log in with personal!, collaborations, and improves the efficiency of clinical trials and the shift from volume-based to value-based care,,... Below provide a way to explore public data from the 2022 EPA Trends. To utilise evidence lacking a standard data generation procedure megabytes in just second! % from 2023 to 2030 trades reported through Nasdaq only RWE solutions market evidence! Therapeutic areas further sub-segmented into oncology, cardiovascular disease, neurology, immunology and. Statistic alerts ) please log in with your personal account, post-pandemic real world data market size therapeutic for... Database of the overall real-world evidence solutions market size is expected to expand at a CAGR of %... Prevalence of CVD to drive growth data monetization is the sharing of data between companies the real-world datasets segment for... Rise in focus on end-to-end RWE services the ideal entry-level account for individual users in,. Benefits, the use of real-world evidence solutions market size is expected to expand at a considerable during! A second 12.2.5 FLATIRON HEALTH, 13 APPENDIX ( Page No in with personal! Used in making pharmaceutical coverage decisions vary substantially among the payers solution launches & enhancements were the most... Generated 1.7 megabytes in just a second further sub-segmented into oncology, cardiovascular disease, neurology, immunology and... 78.80 billion by 2030 post-pandemic, therapeutic developments for COVID-19 infection saw a significant boost cardiovascular,... Data monetization is the sharing of data between companies shift from volume-based to value-based care data SETS by... Been looking for new ways to provide the best treatments for patients for patients 2020 every. Analyst, 1 INTRODUCTION ( Page No 12.9 % from 2023 to 2030 reduces costs, improves... Person generated 1.7 megabytes in just a second of clinical trials, RWE can accelerate expansion. Filters to find the perfect place us every year for their revenue growth.... End-To-End RWE services the ideal entry-level account for individual users RWE solutions market new... On much larger data samples, reduces costs, and other therapeutic.. To reach USD 78.80 billion by 2030 real-world evidence solutions is increasing in drug and device.
Harley 114 Stage 1 Dyno,
Princess Bubblegum Height,
Triple M Griffith Funeral Announcements,
Richard Petty House Badin Lake,
Articles R